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Chemerin is a chemoattractant protein with adipokine properties encoded by the retinoic acid 
receptor responder 2 (RARRES2) gene. it has gained more attention in the past few years due to 
its multilevel impact on metabolism and immune responses. However, mechanisms controlling 
the constitutive and regulated expression of RARRES2 in a variety of cell types remain obscure. 
To our knowledge, this report is the first to show that DNA methylation plays an important role 
in the cell‑specific expression of RARRES2 in adipocytes, hepatocytes, and B lymphocytes. Using 
luciferase reporter assays, we determined the proximal fragment of the RARRES2 gene promoter, 
located from − 252 to + 258 bp, to be a key regulator of transcription. Moreover, we showed that 
chemerin expression is regulated in murine adipocytes by acute‑phase cytokines, interleukin 1β and 
oncostatin M. in contrast with adipocytes, these cytokines exerted a weak, if any, response in mouse 
hepatocytes, suggesting that the effects of IL‑1β and OSM on chemerin expression is specific to fat 
tissue. Together, our findings highlight previously uncharacterized mediators and mechanisms that 
control chemerin expression.
Chemerin is a small (18 kDa) multifunctional protein capable of regulating different biological processes, 
including immune cell migration, adipogenesis, osteoblastogenesis, angiogenesis, myogenesis, and glucose 
 homeostasis1. Moreover, it shows broad-spectrum antimicrobial activity in both human and mouse epider-
mis, suggesting it plays a role in maintaining skin-barrier  homeostasis2,3. Chemerin-induced signaling is medi-
ated predominantly through chemokine-like receptor 1 (CMKLR1), which is expressed by many cells includ-
ing plasmacytoid dendritic cells (pDCs), macrophages, natural killer (NK) cells, adipocytes, hepatocytes, and 
 keratinocytes2,4–9. Chemerin is secreted as pro-chemerin and circulates in plasma as an inactive precursor protein 
(Chem163S) that can subsequently be activated through posttranslational carboxyl-terminal processing by a 
variety of  proteinases10,11.
The gene encoding chemerin is known as retinoic acid receptor responder 2 (RARRES2)12, or as tazarotene-
induced gene 2 (TIG2) given it was first discovered in tazarotene-treated psoriatic skin  lesions13,14. Liver and 
adipose tissue are reported to be the major sites of chemerin production; nonetheless, RARRES2 mRNA is detect-
able in many other tissues, including the adrenal glands, ovaries, pancreas, lungs, kidney, and  skin2,15. Chemerin 
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expression in these tissues may be constitutive and/or  regulated1. It is likely that these pathways are controlled 
differently. For example, adipocytes and hepatocytes show high constitutive RARRES2 mRNA  levels15, whereas 
the chemerin transcript is not detectable in bone marrow or immune cells, such as monocytes or  granulocytes16. 
So far, it has not been determined what controls the on/off “switch” of the chemerin expression in different cells.
Chemerin expression may be regulated by a variety of inflammatory and metabolic mediators in a manner 
dependent on cell  type17. These factors can be broadly classified as (1) agonists of nuclear receptors (retinoids, 
vitamin D, glucocorticoids), (2) factors mainly associated with metabolic processes (e.g. fatty acids, insulin, 
glucose) and (3) immunomodulatory mediators (e.g. cytokines of acute or chronic inflammation and lipopoly-
saccharide (LPS)1. The molecular mechanisms underlying the regulated expression of chemerin are poorly 
understood. Analysis of the chemerin promoter has identified functional response elements for the peroxisome 
proliferator-activated receptor γ (PPARγ), farnesoid X receptor (FXR), and sterol regulatory element-binding 
protein 2 (SREBP2) in the mouse chemerin  promoter18–20. These factors are regulated by lipids (PPARγ), bile 
acids (FXR), or free fatty acids (SREBP2).
Altered chemerin expression may be of relevance in the context of various pathological conditions like obesity, 
cancer, and  inflammation6,21,22. Therefore, developing a better understanding of mechanisms underlying constitu-
tive and regulated chemerin expression is of particular importance. In the present study, we demonstrate that the 
constitutive expression of chemerin is controlled by the DNA methylation of RARRES2, while the proximal region 
of the gene promoter is the key regulator of transcription. Moreover, using various experimental approaches we 
show that acute-phase cytokines, interleukin 1b (IL-1β) and oncostatin M (OSM), regulate chemerin expression 
in mouse primary adipocytes but not in hepatocytes, both in vitro and in vivo. As such, we provide novel insights 
into the mechanisms and factors affecting constitutive and regulated chemerin expression.
Results
Chemerin is constitutively expressed in liver and adipose tissue but not in B‑cells. To study 
the constitutive and regulated expression of RARRES2 we queried the Human Protein  Atlas16 to identify cells 
and tissues having, on average, high mRNA levels of human chemerin or cells with very low or undetectable 
transcript levels. The liver, adrenal gland, pancreas, and white adipose tissue (WAT) show high chemerin mRNA 
levels but the transcript is not detectable in B lymphocytes, monocytes or granulocytes (Fig. 1A). Liver, WAT and 
B-cells were chosen for further analyses. Consistent with human data, RT-QPCR demonstrated that RARRES2 
was constitutively expressed in liver and WAT tissue but not in B-cells in mice (Fig. 1B).
IL‑1β and OSM stimulation upregulates RARRES2 expression in murine adipocytes but not 
hepatocytes. Next, we questioned how chemerin expression can be regulated in cells with apparent con-
stitutive expression of RARRES2. WAT and the liver have been reported by multiple studies to be key sites of 
chemerin  production1. Both organs contribute to fatty acid metabolism, respond to numerous cytokines and 
are involved in the pathogenesis and pathophysiology of  obesity23 which is linked to elevated systemic levels of 
 chemerin22. Among the potential regulators of systemic chemerin levels are the acute-phase mediators OSM and 
IL-1β, which, as we showed previously, regulate chemerin levels in human epidermis-like  cultures2. Moreover, 
liver and fat tissue are known to be responsive to both OSM and IL-1β24–27, suggesting that chemerin expression 
will be also regulated by these mediators in both adipocytes and hepatocytes. Treatment of epididymal white 
adipose tissue (eWAT)-derived mouse adipocytes with OSM and/or IL-1β resulted in statistically significant and 
comparable upregulation of RARRES2 mRNA by each stimulus (Fig. 1C). In parallel, secreted chemerin protein 
levels tended to be higher after 48-h of stimulation with the cytokines as compared with the control (Fig. 1D). 
In contrast with the adipocytes, downregulation of RARRES2 mRNA was detected in hepatocytes in response 
to OSM or OSM + IL-1β but not IL-1β alone (Fig. 1C). Likewise, cytokines did not affect the chemerin protein 
levels in hepatocyte-conditioned media (Fig. 1D). These in vitro results were corroborated by in vivo findings. 
RARRES2 mRNA was upregulated only in eWAT (Fig. 1F) but not in the liver (Fig. 1G) after in vivo IL-1β + OSM 
administration. We confirmed that primary hepatocytes and mouse liver tissue responded to stimulation with 
IL-1β and OSM, since SAA3 mRNA levels, encoding an acute-phase protein, was markedly elevated (Fig. 1E,H). 
Together, these results suggest that the effect of cytokines that results in the upregulation of chemerin expression 
is specific to fat tissue.
Adipocytes are key cells expressing chemerin after stimulation with acute‑phase 
cytokines. The stromal vascular fraction (SVF) of adipose tissue consists of a heterogeneous population 
of cells that includes adipocyte precursors, hematopoietic stem cells, endothelial cells, fibroblasts, and immune 
 cells28. Therefore, we next asked whether adipocytes are the main cells that express chemerin in response to 
acute-phase cytokines. Indeed, we found a similar chemerin expression pattern and levels in both eWAT-derived 
adipocytes and in adipocytes derived from sorted SCA-1+ adipogenic progenitors (Fig. 2A–D). Chemerin tran-
script levels continued to rise throughout a five-day time course. Stimulation with IL-1β and IL-1β + OSM 
yielded the highest mRNA levels (characterized by an approximately 12- to 13-fold increase relative to the one-
day control) in both types of adipocyte cell culture (Fig. 2A,C). However, statistically significant upregulation 
of chemerin protein levels was observed only in the eWAT derived adipocytes treated by IL-1β + OSM or in the 
cell culture of sorted adipogenic precursors following IL-1β and IL-1β + OSM stimulation. Accordingly, we con-
cluded that IL-1β and OSM regulate chemerin expression primarily in adipocytes. Chemerin protein production 
was highest in response to IL-1β + OSM, suggesting the existence of additive effects.
DNA methylation affects constitutive RARRES2 expression. We next investigated DNA meth-
ylation of the RARRES2 promoter region as a possible mechanism underlying  differential29 constitutive and 
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Figure 1.  Chemerin is constitutively expressed in the liver and WAT. Acute-phase cytokines upregulate chemerin expression 
in the adipocytes of WAT but not in hepatocytes. The Human Protein Atlas was used to compare human chemerin mRNA 
levels across multiple tissues and cells (A). B-cells, WAT, and liver tissue were chosen for further studies. Afterward, lymph 
nodes, liver tissue, and eWAT depots were excised from C57Bl6 mice and subjected to RT-QPCR analysis or isolation of 
B-cells, primary hepatocytes, or the SVF of eWAT. Relative chemerin mRNA levels across murine B-cells, liver tissue, and 
WAT are shown (B). SVF cells were differentiated to obtain a mature adipocyte cell culture. Then, the cells were treated 
with IL-1β (10 ng/mL), OSM (50 ng/mL), or a combination for 48 h. The levels of chemerin (C) and SAA3 (E) mRNA 
were determined using RT-QPCR. The relative expression of stimulated cells over the control is shown. Levels of secreted 
chemerin were determined in parallel in conditioned media by ELISA (D). Data are presented as the mean ± SD of at least 
three independent experiments. Statistical significance between the control and treated cells is shown by an asterisk; *p < 0.05 
by ANOVA followed by a Bonferroni post-hoc test. In vivo, IL-1β and OSM were injected intraperitoneally at doses of 10 μg/
kg BW and 160 μg/kg BW, respectively. After 48 h, liver tissue and eWAT were isolated and subjected to RT-QPCR analysis. 
The levels of chemerin mRNA in eWAT (F) or liver tissue (G) and SAA3 (H) were determined. Data are presented as the 
mean ± SD of at least three independent experiments. Statistical significance between the control (PBS) and the cytokine-
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regulated chemerin expression in various cell types. We studied DNA fragments ranged ranging in location 
from − 735 to + 258 bp of the RARRES2 gene because promoter sequences are typically defined as being 100 
to 1,000  bp upstream of the transcription start site and 100  bp downstream of the transcription start  site30. 
Moreover, this DNA region contains all the binding sites of previously characterized transcription factors (TFs) 
of RARRES218–20.
Using bisulfite sequencing we determined the methylation status of the murine RARRES2 gene in B-cells 
that do not produce chemerin, as well as that in unstimulated and cytokine-treated adipocytes and hepatocytes. 
We identified 17 CpG sites located within − 735/+ 258 bp of RARRES2 (Fig. 3A). However, a computational 
analysis of this sequence did not identify any CpG island (data not shown). The chemerin promoter was found 
to be highly methylated in B lymphocytes. In contrast, our results suggested a much lower methylation status 
of the chemerin promoter in unstimulated adipocytes and hepatocytes relative to in B-cells (Fig. 3B). Interest-
ingly, the upregulation of chemerin expression after stimulation of adipocytes with IL-1β and OSM is correlated 
with the statistically significant increase in the average methylation level of the RARRES2 gene promoter within 
− 735/− 253 bp (Fig. 3C) but not − 252/+ 258 bp (Fig. 3D). However, the methylation pattern of the chemerin 
promoter was not altered in the cytokine-treated but chemerin-unresponsive primary cultures of mouse hepato-
cytes. We concluded that DNA methylation plays a role in controlling the constitutive expression of chemerin 
and affects cytokine-regulated expression in adipocytes.
the proximal part of the RARRES2 promoter is a key regulator of transcription. To test how 
cytokines or DNA methylation can regulate the transcription of RARRES2, we established the following three 
reporter constructs containing different portions of chemerin promoter sequences: Chemerin_Full (position 
− 735/+ 258  bp relative to the transcription start site), Chemerin_Proximal (position − 252/+ 258  bp), and 
Chemerin_Distal (position − 735/− 253 bp) (Fig. 4A). The promoter was divided into two parts based on the 
methylation levels of RARRES2 (Fig. 3B). The average percentage methylation levels for the proximal region was 
less than 14% in both unstimulated adipocytes and hepatocytes whereas the distal part of the promoter showed 
greater average methylation, varying from 28% (hepatocytes) to 40% (adipocytes). We used 3T3-L1 adipocyte 
precursors for transient transfection since these cells produce chemerin and respond to cytokine stimulation in 
a manner similar to that of differentiated adipocytes (Fig. 4B).
Figure 2.  Adipocytes are key cells expressing chemerin following stimulation with IL-1β + OSM. eWAT or 
SCA-1 + APs were isolated. The cells were differentiated to obtain a mature adipocyte cell culture. Then, the 
cells were treated with IL-1β (10 ng/mL), OSM (50 ng/mL), or a combination for up to five days. The levels of 
chemerin mRNA (A, C) were determined using RT-QPCR. The relative expression of stimulated cells over the 
control is shown. Levels of secreted chemerin were determined in parallel in conditioned media by ELISA (B, 
D). Data are presented as the mean ± SEM of at least three independent experiments. Statistical significance 
between the control and the treated cells is indicated by an asterisk; *p < 0.05 by analysis of covariance followed 
by a Bonferroni post-hoc test.
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First, we considered whether the Chemerin_Full construct, which covers all previously characterized TF 
binding  sites18–20, responds to IL-1β + OSM stimulation. However, cytokine treatment did not reach statistical 
significance relative to in the untreated controls (Fig. 4C). To investigate whether inflammation-responsive 
TFs may bind to − 735/+ 258 bp of the RARRES2 promoter sequence in murine adipocytes and hepatocytes, we 
queried ChIP-Atlas31, a resource that gathers publicly available results from chromatin immunoprecipitation-
sequencing experiments. The results showed that inflammation-responsive TFs, including NFκB, AP-1, SAF-1, 
c-Jun/c-Fos, and STATs, do not bind to the − 735/+ 258 bp of the RARRES2 promoter sequence either in adipo-
cytes or in hepatocytes (Table 1).
To determine which part of the RARRES2 promoter region is linked with constitutive chemerin expression, 
3T3-L1 cells were transfected with the Chemerin_Full, Chemerin_Proximal, and Chemerin_Distal constructs, 
respectively. Chemerin_Proximal and Chemerin_Full showed the highest promoter activity as determined by 
luciferase assay (Fig. 4D). The Chemerin_Distal construct had similar promoter activity in comparison with 
the empty vector.
To investigate the role of DNA methylation in the regulation of chemerin expression, we excised the promoter 
sequence from pNL1.1[Nluc] constructs with restriction enzymes, treated the eluted DNA with SssI methylase 
or left it untreated, and relegated the methylated and unmethylated DNA inserts into the parent vector. Promoter 
activity of the methylated Chemerin_Proximal construct was five times lower than that of the unmethylated 
construct (Fig. 4E). In line with the results of bisulfite sequencing (Fig. 3), promoter activity of the methylated 
Chemerin_Distal construct was higher than that of the unmethylated construct.
Together, these data suggest that the DNA sequence of the RARRES2 promoter region located from − 252 to 
+ 258 bp is critical for constitutive chemerin expression and that its methylation suppresses the transcription. 
Figure 3.  Chemerin transcription is linked to the DNA methylation status of the RARRES2 promoter region 
from − 735 to + 258 bp. Primary mouse hepatocytes and mature adipocytes derived from sorted APs were 
treated with IL-1β (10 ng/mL) and OSM (50 ng/mL) for 48 h. B-cells, which do not produce chemerin, were 
adopted as a control. The DNA methylation status of the RARRES2 promoter sequence was analyzed by bisulfite 
sequencing. The localization of CpG sites (A) and the DNA methylation levels of each CpG site from − 735 
to + 258 bp of the RARRES2 promoter are shown (B). The differences in the average methylation level of the 
proximal (C) and distal (D) parts of the promoter were analyzed using the nonparametric Kruskal–Wallis test; 
*p < 0.05. Data are presented as the mean ± SEM of at least three independent experiments.
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Interestingly, the distal part of the chemerin promoter (position − 735/− 253 bp) shows minimal activity which 
is increased when DNA is methylated.
Discussion
Control of gene expression plays a key role in a variety of physiological and pathophysiological processes, rang-
ing from cell differentiation, cellular stress responses, and immunity, to tissue homeostatis. Many mechanisms 
contribute to the regulation of gene expression to ensure coordinated cellular behaviors and fate decisions. This 
includes modifications of DNA (e.g. DNA methylation), binding of TFs to a gene promoter, alternative splicing, 
miRNAs, and many  others32. To date, the molecular mechanisms controlling constitutive and regulated chemerin 
expression are still poorly  understood1. Further, the functional significance of DNA methylation in the regulation 
of RARRES2 transcription has not yet been elucidated.
Figure 4.  The proximal part of the chemerin promoter is a key regulator of transcription. The murine 
RARRES2 promoter regions (from − 735 to + 258 bp) were cloned into the pNL1.1[Nluc]-Basic vector (A). 
3T3-L1 adipocyte precursors were used for transient transfections since these cells respond to IL-1β + OSM 
stimulation similarly to the primary adipocytes (B). 3T3-L1 cells were transfected with Chemerin_Full vector 
(C) or different chemerin promoter constructs (D, E) and eventually stimulated with cytokines. The results are 
expressed as the fold-change in relative luciferase units relative to the empty vector. Statistical significance is 
indicated by an asterisk; *p < 0.05 by ANOVA followed by a Bonferroni post-hoc test. The Mann–Whitney test 
was used to analyze statistical differences between methylated/mock methylated vectors. Data are presented as 
the mean ± SD of at least three independent experiments.
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Here, we determined, for the first time, that CpG sites located between − 735 and + 258 bp of the RARRES2 
promoter are highly methylated in B-cells but not in hepatocytes and adipocytes. This suggests that DNA meth-
ylation controls constitutive chemerin expression in cells of different origins. B-cells do not secrete chemerin; 
meanwhile, hepatocytes and adipocytes are known to express high levels of chemerin and to release the chemerin 
 protein1. This constitutive expression controls tissue homeostasis by affecting physiological processes like immune 
cell migration, angiogenesis, adipogenesis, and energy  metabolism33. Epigenetic regulation by CpG methylation 
in the promoter region is often associated with both tissue-specific and heterogeneous expression of  genes29. 
DNA methylation can cause transcriptional silencing of genes by inhibiting the binding of TFs to regulatory 
 sequences34. Even the methylation status of a single CpG locus can modulate gene  expression35,36. However, we 
have also observed variations in the DNA methylation pattern between the proximal (− 252/+ 258 bp) and distal 
(− 735/− 253 bp) parts of the RARRES2 promoter region in adipocytes and hepatocytes. Therefore, we divided 
the chemerin promoter into two parts to study activity. Luciferase assays revealed that the proximal part of the 
chemerin promoter is a key regulator of constitutive chemerin expression. Methylation of the CpG sites located 
within this region diminished luciferase activity. Finally, the distal part of the chemerin promoter is poorly char-
acterized and did not show any important activity in luciferase assays. Taken together, the DNA methylation of 
the RARRES2 promoter region located from − 252 to + 258 bp regulates the constitutive expression of chemerin 
in a cell-type dependent manner.
The expression of chemerin may be also regulated by various mediators including IL-1β and OSM acute-phase 
cytokines. Both IL-1β, and OSM, are essential mediators of adaptive and innate immune  responses37,38, and both 
have potential roles in the pathology of  psoriasis39,40, rheumatoid  arthritis41,  cancer42, and  obesity43, which are 
diseases with postulated chemerin  involvement6,21, 22,44. We previously showed that IL-1β and OSM upregulated 
Table 1.  TFs that may bind the RARRES2 promoter region located from − 735 to + 258 bp in murine 
adipocytes and hepatocytes. ChIP-Atlas31 raw data linked to the selected records were downloaded and 
submitted to CRUNCH online  tool59 to identify proteins bound to the RARRES2 genomic loci with the binding 
score value of − 10 × log10[q] > 700.
Transcription factor Chromosome Start End SRX ID q-value − 10 × log10[q]
Adipocytes
Nr3c1 chr6 48,522,605 48,522,985 SRX821805 1.00E−100 1,000
Pparg chr6 48,522,627 48,522,940 SRX821796 1.00E−100 1,000
Nr3c1 chr6 48,522,608 48,522,979 SRX821802 5.01E−85 843
Pparg chr6 48,522,641 48,522,924 SRX821794 7.94E−81 801
Pparg chr6 48,522,639 48,522,919 SRX821793 7.94E−74 731
Pparg chr6 48,522,600 48,522,886 SRX821792 7.94E−72 711
Liver
Ppara chr6 48,522,633 48,522,867 SRX5142529 1.00E−100 1,000
Rxra chr6 48,522,578 48,522,927 SRX020176 1.00E−100 1,000
Ncor1 chr6 48,522,654 48,522,891 SRX5028170 1.00E−100 1,000
Ncor1 chr6 48,522,651 48,522,880 SRX5028173 1.00E−100 1,000
Ncor1 chr6 48,522,646 48,522,866 SRX5028172 1.00E−100 1,000
Ncor1 chr6 48,522,662 48,522,870 SRX5028171 1.00E−100 1,000
Ppara chr6 48,522,629 48,522,872 SRX5142530 1.00E−100 1,000
Ppara chr6 48,522,627 48,522,900 SRX5142531 1.00E−100 1,000
Rxra chr6 48,522,625 48,522,927 SRX020179 1.00E−100 1,000
Rxra chr6 48,522,604 48,522,939 SRX020180 1.00E−100 1,000
Ncor1 chr6 48,522,664 48,522,868 SRX5028169 1.00E−100 1,000
Rxra chr6 48,522,585 48,522,946 SRX020175 1.00E−100 1,000
Ncor1 chr6 48,522,657 48,522,869 SRX5028168 1.00E−100 1,000
Hnf4a chr6 48,522,552 48,522,951 SRX547094 1.00E−100 1,000
Hnf4a chr6 48,522,508 48,522,984 SRX2375607 1.00E−100 1,000
Hnf4a chr6 48,522,561 48,522,954 SRX547095 1.00E−100 1,000
Hnf4a chr6 48,522,517 48,522,959 SRX2375608 1.00E−100 1,000
Ppara chr6 48,522,638 48,522,866 SRX5028181 7.94E−96 951
Ppara chr6 48,522,643 48,522,842 SRX5142527 1.26E−95 949
Rxra chr6 48,522,620 48,522,928 SRX4949978 1.58E−94 938
Ppara chr6 48,522,637 48,522,885 SRX5028184 3.16E−92 915
Cebpb chr6 48,522,643 48,522,907 SRX661416 1.58E−86 858
Ppara chr6 48,522,640 48,522,853 SRX5028180 1.58E−82 818
Ppara chr6 48,522,646 48,522,888 SRX5028185 7.94E−80 791
Rxra chr6 48,522,524 48,522,942 SRX6658445 5.01E−71 703
8
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:13702  | https://doi.org/10.1038/s41598-020-70625-7
www.nature.com/scientificreports/
chemerin expression in human skin  cultures2. Here, our research revealed that a combination of both cytokines 
considerably increased RARRES2 mRNA and protein levels in cell cultures of murine eWAT-derived adipocytes 
and differentiated SCA1 + APs but not in primary hepatocytes. This result is in agreement with those reported by 
Kralisch et al.45 who found that IL-1β increased chemerin expression in 3T3-L1 adipocytes. Also, these in vitro 
results were corroborated by in vivo findings: RARRES2 mRNA was elevated in eWAT but not in the liver and 
chemerin was up-regulated, on average, by 1.5- to 2.0-fold in eWAT. Although this increase in chemerin levels was 
not robust, eWAT-mediated local production and/or activation of chemerin may play an important role in main-
taining tissue homeostasis and should be considered in addition to systemic levels of circulating  chemerin1,46,47. 
In contrast with adipocytes, IL-1β and OSM did not affect chemerin expression in hepatocytes. The existence of 
differential regulation of chemerin expression in the liver and adipose tissue in response to other mediators has 
also been reported by other research  groups17,48. So far, only FFAs and GW4064, a synthetic FXR agonist, have 
been shown to influence chemerin expression in  hepatocytes19.
We also asked how the RARRES2 promoter region affects the regulated expression of chemerin. Analysis of 
the Chemerin_Full construct did not reveal any statistically significant degree of activation over the unstimulated 
control when transfected cells were stimulated with IL-1β and OSM. The Chemerin_Full vector, which covers 
− 735 to + 258 bp region of the murine RARRES2 gene, contains all previously characterized functional TF bind-
ing sites: including the PPAR response  element20, FXR response  element19, and SREBP2 binding  site18. Acute 
phase cytokines can impact the expression of inflammatory-responsive genes by a variety of TFs including NFκB, 
AP-1, c-Jun/c-Fos, IRF1 or  STAT149–52. However, our search of the ChIP-Atlas  database31 did not reveal that any 
of the listed TFs were able to bond to the − 735/+ 258 bp of the RARRES2 promoter region either in adipocytes or 
hepatocytes. This may indicate that inflammation-responsive TFs binding sites are located outside of the inves-
tigated promoter region or that other mechanisms and/or cis-regulatory elements affect chemerin expression.
Interestingly, the upregulation of chemerin expression after stimulation of adipocytes with cytokines corre-
lated with a statistically significant increase in the average methylation level of the distal region of the RARRES2 
promoter. The methylation pattern was not altered in cytokine-treated but chemerin-unresponsive primary 
cultures of mouse hepatocytes. Methylation of the Chemerin_Distal construct increased luciferase activity when 
compared with the unmethylated vector, but such was still far below the activity of the unmethylated proximal 
region. DNA methylation is typically associated with gene silencing although CpG methylation of the DNA and, 
like methylation of the CRE sequence, may enhance the DNA binding of  TFs53.
In summary, our studies reveal novel insights into the mechanisms and factors regulating chemerin expres-
sion and secretion. For the first time, we show that DNA methylation may control the constitutive expression of 
RARRES2, and that the proximal region of the gene promoter is the key regulator. Acute-phase cytokines affect 
chemerin expression in a cell-type dependent manner, both in vitro and in vivo. The investigated RARRES2 pro-
moter region was unresponsive to acute-phase cytokine stimulation. These findings provide a basis for further 
investigations of the regulation of chemerin transcription.
Methods
Materials. If not stated differently, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Roswell Park Memorial Institute (RPMI)-1640 medium was obtained from Biowest. Dulbecco’s Modified Eagle 
medium (DMEM), DMEM:F12 medium, and phosphate-buffered saline (PBS) buffer were purchased from PAN 
Biotech (Aidenbach, Germany). FBS was purchased from Gibco Laboratories (Gaithersburg, MD, USA). Bovine 
serum albumin (BSA), ethylenediaminetetraacetic acid (EDTA), and trypan blue were purchased from Bio-
Shop. Collagenase D was obtained from Roche Holding AG (Basel, Switzerland). Mouse recombinant IL-1β and 
OSM were purchased from R&D Systems (Minneapolis, MN, USA). Fc block [rat–anti-mouse cluster of dif-
ferentiation (CD)16/32, #101310], biotin-conjugated rat–anti-mouse CD45 (#103104), biotin-conjugated rat–
anti-mouse CD31 (#102404), and PE-conjugated rat–anti-mouse Ly-6A/E (#108108) antibodies were purchased 
from Biolegend (San Diego, CA, USA). Lineage selection columns, lineage depletion columns, anti-biotin, and 
anti-PE magnetic beads were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). PCR primers 
were obtained from Genomed (Leesburg, FL, USA).
Animal studies. Male eight- to 12-week-old C57BL/6 mice were used for these investigations. The mice 
were maintained under specific pathogen-free conditions at the Faculty of Biochemistry, Biophysics, and Bio-
technology of Jagiellonian University animal care facility. IL-1β and OSM were injected intraperitoneally at 
doses of 10 μg/kg BW and 160 μg/kg BW, respectively. After 48 h, the liver and eWAT were isolated and subjected 
to RT-QPCR analysis. All experimental procedures were approved by the First Local Ethical Committee on 
Animal Testing at the Jagiellonian University in Krakow, Poland (permit no. 41/2014), in accordance with the 
Guidelines for Animal Care and Treatment of the European Community. The mice were sacrificed by an over-
dose of anesthesia (a mixture of ketamine and xylasine), followed by cervical dislocation.
primary hepatocytes isolation and culture. Primary hepatocytes were isolated from C57BL6 mice 
with a modified two-step perfusion method according to the protocol described by  Seglen54. Briefly, the mice 
were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) intraperitoneally and the abdomen was 
opened under sterile conditions. Following cannulation of the portal vein, the liver was perfused with solu-
tion I [100 µM of EGTA in Krebs–Ringer (K–R) buffer], followed by solution II (1 mg/mL of collagenase D in 
K-R buffer supplemented with 150 µM of  CaCl2). Then, the liver was dissected, passed through a 100-µm cell 
strainer, and centrifuged (60 g, five minutes, 10 °C). The isolated hepatocytes were suspended in DMEM:F12 
medium supplemented with 10% FBS, 50 µg/mL of gentamycin, 6 ng/mL of insulin, and 400 ng/mL of dexa-
methasone. Viable cells were counted using trypan blue staining and seeded on a collagen-coated plate at a den-
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sity of 1 × 105 cells/cm2. Cells were cultured at 37 °C in the presence of 5%  CO2 for four hours. Afterward, plated 
cells were washed with DMEM:F12 medium and stimulated with IL-1β (10 ng/mL) and OSM (50 ng/mL) for 
48 h. At the time of harvest, cell culture media supernatants were collected and RNA lysis buffer (Fenozol Plus; 
A&A Biotechnology, Gdynia, Poland) or radioimmunoprecipitation assay buffer containing protease inhibitors 
(Roche Holding AG, Basel, Switzerland) were added to the specified wells. Collected samples were subjected to 
RT-QPCR or enzyme-linked immunosorbent assay (ELISA) analysis.
Isolation and culture of adipose tissue‑derived stromal vascular fraction (SVF). eWAT depots 
were isolated from 8- to 10-week-old male C57BL6 mice, minced, and digested with collagenase D (3.5 mg/mL) 
in K–R buffer supplemented with 2% BSA and 150 μM of  CaCl2 for one hour in 37 °C water bath with shaking 
every five minutes. Digested tissue was then centrifuged (280 g, 10 min, 15 °C), washed, filtered through 100 μm 
of cell strainer, and centrifuged. Then, the pellet was suspended in red blood cell lysis buffer (155 mM of  NH4Cl, 
12 mM of  NaHCO3, 0.1 mM of EDTA) for three minutes at room temperature, centrifuged, and suspended 
in DMEM:F12 medium (20% FBS, gentamycin 50 μg/mL). Isolated SVF cells were then seeded at a density of 
9 × 104 cells/cm2 on a culture plate. Attached cells were washed and replenished with fresh medium after 24 h 
to discard unattached dead cells or immune cells and, by the third day, more than 90% of cells displayed typical 
fibroblastic morphology. Then, the SVF culture was subjected to adipocyte differentiation.
isolation and culture of adipogenic progenitors. Adipogenic progenitors (APs) were isolated from 
C57BL6 mice according to the protocol described by Lee et al.55. eWAT was digested, filtered, and washed as 
described above. APs were then isolated first using negative selection of CD45 and CD31 and then positive selec-
tion for SCA-1. Briefly, SVF cells were suspended in MACS buffer (0.5% BSA, 2 mM of EDTA, 50 µg/mL of gen-
tamycin) and preincubated with Fc block [rat–anti-mouse CD16/32 monoclonal antibody (mAb), 45 µg/mL], 
which was followed by incubation with biotin-conjugated antibodies against CD45 (rat–anti-mouse CD45 mAb) 
and CD31 (rat–anti-mouse CD31 mAb), both 7.5 μg/mL. Then, SVF cells were incubated with streptavidin-
conjugated magnetic beads, washed, and passed over a lineage depletion column to exclude endothelial cells and 
leukocytes. The flow-through was collected, washed, and incubated with PE-conjugated anti-SCA-1 (rat–anti-
mouse Ly-6A/E mAb, 4.8 μg/mL), followed by anti–PE-conjugated magnetic beads. Cells were then washed and 
passed over a lineage selection column. Labeled cells were collected, suspended, in DMEM:F12 medium (20% 
FBS, gentamycin 50 μg/mL), counted, seeded on a cell culture flask, and expanded. Then, the cells were replated 
at a density of 2.5 × 104 cells/cm2 and subjected to adipocyte differentiation in adipocyte maintenance medium.
Adipocyte differentiation. Differentiation was induced when SVF cells or APs reached 90% confluence. 
Cells were switched to adipocyte differentiation medium (DMEM:F12, 8% FBS, 8 µg/mL of biotin, 50 µg/mL of 
gentamycin, 1.15 µg/mL of insulin, 80 µg/mL of IBMX, 1.5 µg/mL of troglitasone, 0.4 µg/mL of dexamethasone) 
for 4  days. Subsequently, adipocyte differentiation medium was changed to adipocyte maintenance medium 
(DMEM:F12, 8% FBS, 8 µg/mL of biotin, 50 µg/mL of gentamycin, 1.15 of µg/mL insulin) for another seven 
days. Subsequently, the cells were stimulated with cytokines as described above.
isolation of B lymphocytes. Popliteal and axillary lymph nodes and the spleen were dissected and pressed 
through 40-µm mesh. Cells were washed with RPMI-1640, centrifuged (300 g, 6 min, 4 °C), and the pellet was 
suspended in red blood cell lysis buffer for five minutes at room temperature. Cells were centrifuged and sus-
pended in MACS buffer (3% FBS, 10 mM of EDTA in PBS). B-cell magnetic sorting was conducted using the 
MagniSort Negative Selection Protocol II (MagniSort Mouse B-cell Enrichment Kit; Affymetrix, Santa Clara, 
CA, USA). Negatively selected cells were suspended in PBS and DNA extraction was performed.
3T3‑L1 cell line culture and cytokine stimulation. The primary mouse preadipocyte cell line 3T3-L1 
was purchased from the American Type Culture Collection. 3T3-L1 cells were grown in DMEM medium sup-
plemented with 10% FBS and gentamycin (50 µg/mL). Cells were seeded at a density of 8 × 103 cells/cm2 on a 
culture plate. After 24 h, the medium was changed and cells were stimulated with IL-1β (10 ng/mL) and OSM 
(50 ng/mL) for 48 h. At the time of harvesting, cell culture media was removed and RNA lysis buffer was added. 
Collected samples were subjected to RT-QPCR analysis.
RT‑QPCR. Total RNA was extracted with the Total RNA Zol-Out Kit (A&A Biotechnology, Gdynia, Poland) 
and converted to complementary DNA using NxGen M-MulV reverse transcriptase (Lucigen Corporation, 
Middleton, WI, USA) with random primers (Promega Corporation, Madison, WI, USA). Real-time PCR was 
performed on the CFX96 thermocycler (Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green I con-
taining universal PCR master mix (A&A Biotechnology, Gdynia, Poland) and the following primers specific to 
mice: chemerin (5′-CTT CTC CCG TTT GGT TTG ATTG, 5′-TAC AGG TGG CTC TGG AGG AGTTC), SAA3 (5′-
ACA GCC AAA GAT GGG TCC AGT TCA , 5′-ATC GCT GAT GAC TTT AGC AGC CCA ), cyclophilin A (5′-AGC 
ATA CAG GTC CTG GCA TCT TGT , 5′-CAA AGA CCA CAT GCT TGC CAT CCA ) and β-actin (5′-CCT TCT TGG 
GTA TGG AAT CCTG, 5′-TGG CAT AGA GGT CTT TAC GGA). The Microsoft Excel–based (Microsoft Corpora-
tion, Redmond, WA, USA) application Best-Keeper was used to analyze the expression stabilities of commonly 
used reference  genes56. Based on this analysis, murine cyclophylin A and β-actin were selected as housekeeping 
genes for normalizing RNA expression in RT-QPCR. Relative gene expression normalized to the geometric 
mean of these housekeeping genes was calculated using the  2−ΔΔCT  method57.
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ELISA. Chemerin levels in cell culture supernatants were quantified by mouse-specific ELISA. MaxiSorp 
Nunc-Immuno Module (Thermo Fisher Scientific, Waltham, MA, USA) strips were coated with rat–anti-mouse 
mAb (MAB23251; R&D Systems, Minneapolis, MN, USA) in Tris-buffered saline (50 mM of Tris–HCl with 
pH of 9.5, 150 mM of NaCl). The plates were then washed with PBS containing 0.1% Tween 20 and nonspecific 
protein-binding sites were blocked with 3% BSA in PBS. Mouse recombinant chemerin was used as a stand-
ard. Chemerin was detected using biotin-conjugated rat–anti-mouse chemerin mAb (BAM2325), followed by 
streptavidin–horseradish peroxidase (BD Biosciences, San Jose, CA, USA). The reaction was developed with 
TMB substrate (BD Biosciences, San Jose, CA, USA). The results were normalized to total protein content in 
the corresponding cell RIPA lysates (Quick Start Bradford Protein Assay; Bio-Rad Laboratories, Hercules, CA, 
USA). ELISA detected both the 163S and 157S chemerin.
Bisulfite genomic DNA sequencing. Genomic DNA was extracted from B-cells, hepatocytes, or dif-
ferentiated APs using the GeneJET Genomic DNA Purification Kit. Genomic DNA aliquots were then treated 
with sodium bisulfite using the EZ DNA Methylation-direct Kit (Zymo Research, Irvine, CA, USA). The targeted 
region of the RARRES2 promoter was amplified with PCR (ZymoTaq PreMix; Zymo Research, Irvine, CA, USA) 
using the following sets of primers specific to converted DNA: range − 717/+ 229 (5′-GAG AGA TTG AGT TGG 
GGA AAT GAG -3′ sense, 5′-CCC CAA CCT CTT TCT AAT ACC TTA -3′ antisense, 62.0 °C), range − 246/+ 154 (5′-
ATG ATA AAG GAA AGG TAA AGG AAA GAT TGG G-3′ sense, 5′-AAA CAA CTC CCT AAC AAT TAT TCC CTC 
TCA CC-3′ antisense, 53.0 °C), range − 459/− 160 (5′-GAT GTT TGG TAG GTA GAT GAA GGT AGT AGT TAGT-
3′ sense, 5′-AAC TAC CAT CAA AAC AAC TAT CCC CAAC-3′ antisense, 58. 9  °C), range − 813/− 337 (5′-TAG 
GGA AAA GGT TTA TTT GGT TAG TAG AGA -3′ sense, 5′-AAA AAA ACT AAA ACT CCT TCA ATA CCA AAA -3′ 
antisense, 50.2 °C). PCR products were then separated on 2% agarose gel and extracted with Gel-Out Concen-
trator (A&A Biotechnology, Gdynia, Poland). Purified DNA was cloned into pTZ57R/T vector (InsTAclone 
PCR Cloning Kit; Thermo Fisher Scientific, Waltham, MA, USA). After transformation and culturing of the 
competent bacteria (Top10 Escherichia coli; Thermo Fisher Scientific, Waltham, MA, USA) overnight on an LB/
agar/ampicillin plate, at least eight colonies were randomly selected, plasmids were recovered using the GeneJET 
Plasmid Miniprep Kit, and the DNA was sequenced with M13 common sequencing primers. The results were 
analyzed using the QUMA online tool (RIKEN, Tsukuba, Japan).
plasmid construction and in vitro methylation. Livers from C57BL6 mice were dissected and genomic 
DNA was isolated using the GeneJET Genomic DNA Purification Kit. The RARRES2 promoter sequence was 
amplified using Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific, Waltham, MA, USA) and 
the following overlap extension PCR (OE-PCR) primers: 5′-CTC GAG GAT ATC AAG ATC TGG CCT CGA AGC 
TTT CAG CTC CTC AGA CAG GAA-3′ and 5′-GCT TTA CCA ACA GTA CCG GAT TGC CAA GTG GTA CCT TGA 
AAA TGA TCA GGT TTG TT-3′ (− 735/+ 258; Chemerin_Full). The resulting PCR product was subcloned into 
the promoterless pNL1.1[Nluc] vector (#N1001; Promega Corporation, Madison, WI, USA) using OE-PCR 
as described by Bryksin and  Matsumura58. Two additional constructs were then created using pNL1.1[Nluc]_
Chemerin_Full as a template and the following OE-PCR primers: 5′-CTC GAG GAT ATC AAG ATC TGG CCT 
CGA TCT GTC AAA AAA CGG CTC CCT CAA GTG -3′ and 5′-CAC TTG AGG GAG CCG TTT TTT GAC AGA TCG 
AGG CCA GAT CTT GAT ATC CTC GAG -3′ (− 252/+ 258; Chemerin_Proximal), 5′-GAA GAT CAC CTG GTC 
AAG CGG GGC TTG GCA ATC CGG TAC TGT TGG TAA AGC-3′ and 5′-GCT TTA CCA ACA GTA CCG GAT TGC 
CAA GCC CCG CTT GAC CAG GTG ATC TTC-3′ (− 735/− 253; Chemerin_Distal). The integrity and orientation 
of the inserts were confirmed by sequencing. Plasmids were amplified in E. coli and purified using Plasmid MIDI 
AX kit (A&A Biotechnology, Gdynia, Poland). For in vitro methylation studies, the constructs were digested 
with NcoI and BglII (New England BioLabs, Ipswitch, MA, USA) and inserts and vectors bands were separated 
and extracted from the agarose gel. Inserts were then incubated for one hour at 37 °C in the presence or absence 
of SssI methylase (New England BioLabs, Ipswitch, MA, USA). The efficiency of the methylation reaction was 
verified by resistance to cleavage using the methylation-sensitive restriction enzyme HpaII (New England Bio-
Labs, Ipswitch, MA, USA). The methylated and mock-methylated chemerin promoter fragments were re-ligated 
into the parent vector, purified using Clean-Up Concentrator (A&A Biotechnology, Gdynia, Poland), and used 
for transfection.
transient transfection and luciferase assay. 3T3-L1 cells were seeded at a density of 1.5 × 104 cells in a 
24-well culture plate and, 24 h later, cells were transfected using ViaFect transfection reagent (Promega Corpora-
tion, Madison, WI, USA). The total amount of DNA used for transfection per well was 0.8 μg, including approx. 
0.5  μg of pNL1.1[Nluc] (equimolar concentrations of empty pNL1.1[Nluc], pNL1.1[Nluc]_Chemerin_Full, 
pNL1.1[Nluc]_Chemerin_Proximal, or pNL1.1[Nluc]_Chemerin_Distal) and 0.3 μg of the pGL4.54 [luc2/TK] 
vector (Promega Corporation, Madison, WI, USA) expressing the Firefly luciferase that was used as an inter-
nal control. Twenty-four hours after transfection, a portion of the cells was stimulated with IL-1β (10 ng/mL) 
and OSM (50 ng/mL) for 48 h. For methylation studies, cells were transfected with 0.5 μg of ligation reactions 
from the methylated/mock-methylated pNL1.1[Nluc]/chemerin promoter constructs and 0.3 μg of the pGL4.54 
[luc2/TK] vector. The amount of DNA per well was equalized using mock plasmid DNA (pcDNA3.1; Promega). 
Forty-eight hours later, the cells were harvested by scraping into a passive lysis buffer (Promega Corporation, 
Madison, WI, USA). NanoLuc and Firefly activities in cell lysates were measured using the Nano-Glo Dual-
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Identification of TFs that bind to RARRES2 promoter using ChIP‑Seq. To investigate which TFs 
bind to RARRES2 promoter sequence, we queried ChIP-Atlas31. Raw data linked to selected records were sub-
mitted to the CRUNCH online tool for peak  verification59. We focused on the peaks with the q-value for statisti-
cal significance below 1/(1070).
Statistical analysis. All data were analyzed using STATISTICA 13 (StatSoft, Tulsa, OK, USA), visualized 
with Prism (GraphPad Software, San Diego, CA, USA), and presented as mean ± standard deviation (SD) or 
mean ± standard error of the mean (SEM). The Student’s t-test was used for comparison between two groups. 
For multiple comparisons, either analysis of variance (ANOVA) with the Bonferroni post-hoc test or Kruskal–
Wallis ANOVA was used. For experiments with repeated measures over time, analysis of covariance with the 
Bonferroni post-hoc test was used instead. Differences were considered statistically significant for p-values of 
less than 0.05.
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